Matt Miksic
Stock Analyst at Barclays
(3.93)
# 609
Out of 4,670 analysts
251
Total ratings
62.69%
Success rate
5.81%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATEC Alphatec Holdings | Maintains: Overweight | $19 → $20 | $10.06 | +98.81% | 1 | Nov 19, 2024 | |
| PODD Insulet | Maintains: Equal-Weight | $220 → $234 | $262.93 | -11.00% | 7 | Nov 11, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $58 → $60 | $30.81 | +94.74% | 5 | Nov 8, 2024 | |
| ABT Abbott Laboratories | Maintains: Overweight | $143 → $149 | $117.76 | +26.53% | 27 | Nov 5, 2024 | |
| SYK Stryker | Maintains: Overweight | $402 → $418 | $384.85 | +8.61% | 22 | Oct 31, 2024 | |
| INMD InMode | Maintains: Overweight | $29 → $27 | $19.02 | +41.96% | 10 | Oct 14, 2024 | |
| EW Edwards Lifesciences | Maintains: Overweight | $90 → $80 | $70.48 | +13.51% | 26 | Sep 9, 2024 | |
| MDT Medtronic | Maintains: Overweight | $104 → $105 | $86.21 | +21.80% | 20 | Aug 22, 2024 | |
| BSX Boston Scientific | Maintains: Overweight | $78 → $86 | $90.00 | -4.44% | 15 | Aug 22, 2024 | |
| GMED Globus Medical | Maintains: Overweight | $85 → $93 | $84.72 | +9.77% | 13 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $138 → $113 | $72.83 | +55.16% | 5 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $490 → $510 | $547.87 | -6.91% | 6 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $130 → $125 | $110.22 | +13.41% | 5 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $16 | $14.17 | +12.91% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $57 → $61 | $51.32 | +18.86% | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $18 | $19.57 | -8.02% | 4 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $52 → $54 | $33.21 | +62.60% | 19 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $158 → $162 | $155.17 | +4.40% | 10 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $96 | $85.99 | +11.64% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $75.08 | +33.19% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $225.89 | +85.05% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $12.82 | +118.41% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $18.77 | +256.95% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $11.49 | +4,077.55% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $23.58 | +268.96% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $4.05 | +517.28% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $9.20 | -2.17% | 1 | Dec 12, 2016 |
Alphatec Holdings
Nov 19, 2024
Maintains: Overweight
Price Target: $19 → $20
Current: $10.06
Upside: +98.81%
Insulet
Nov 11, 2024
Maintains: Equal-Weight
Price Target: $220 → $234
Current: $262.93
Upside: -11.00%
Tandem Diabetes Care
Nov 8, 2024
Maintains: Overweight
Price Target: $58 → $60
Current: $30.81
Upside: +94.74%
Abbott Laboratories
Nov 5, 2024
Maintains: Overweight
Price Target: $143 → $149
Current: $117.76
Upside: +26.53%
Stryker
Oct 31, 2024
Maintains: Overweight
Price Target: $402 → $418
Current: $384.85
Upside: +8.61%
InMode
Oct 14, 2024
Maintains: Overweight
Price Target: $29 → $27
Current: $19.02
Upside: +41.96%
Edwards Lifesciences
Sep 9, 2024
Maintains: Overweight
Price Target: $90 → $80
Current: $70.48
Upside: +13.51%
Medtronic
Aug 22, 2024
Maintains: Overweight
Price Target: $104 → $105
Current: $86.21
Upside: +21.80%
Boston Scientific
Aug 22, 2024
Maintains: Overweight
Price Target: $78 → $86
Current: $90.00
Upside: -4.44%
Globus Medical
Aug 8, 2024
Maintains: Overweight
Price Target: $85 → $93
Current: $84.72
Upside: +9.77%
Jul 29, 2024
Maintains: Equal-Weight
Price Target: $138 → $113
Current: $72.83
Upside: +55.16%
Jul 23, 2024
Maintains: Overweight
Price Target: $490 → $510
Current: $547.87
Upside: -6.91%
May 31, 2024
Maintains: Underweight
Price Target: $130 → $125
Current: $110.22
Upside: +13.41%
Mar 5, 2024
Maintains: Underweight
Price Target: $13 → $16
Current: $14.17
Upside: +12.91%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $57 → $61
Current: $51.32
Upside: +18.86%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $17 → $18
Current: $19.57
Upside: -8.02%
Feb 12, 2024
Maintains: Overweight
Price Target: $52 → $54
Current: $33.21
Upside: +62.60%
Oct 12, 2023
Maintains: Equal-Weight
Price Target: $158 → $162
Current: $155.17
Upside: +4.40%
May 13, 2022
Assumes: Outperform
Price Target: $96
Current: $85.99
Upside: +11.64%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $75.08
Upside: +33.19%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $225.89
Upside: +85.05%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $12.82
Upside: +118.41%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $18.77
Upside: +256.95%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $11.49
Upside: +4,077.55%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $23.58
Upside: +268.96%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $4.05
Upside: +517.28%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $9.20
Upside: -2.17%